Neoadjuvant Treatment of Breast Cancer Using
Name of the Trial
Why This Trial Is Important
Researchers want to compare AI therapy and chemotherapy as neoadjuvant (before surgery) treatments for breast cancer, but first they need to determine which AI(s) to use in such a comparison. Neoadjuvant therapy may shrink tumors enough to allow a woman to undergo breast-sparing surgery instead of mastectomy.
In this trial, women with estrogen-responsive (i.e., estrogen receptor-positive) breast cancer will be treated with one of three AIs - exemestane (Aromasin), letrozole (Femara), or anastrozole (Arimidex) - before surgery to determine which AI(s) to use in a future trial that compares neoadjuvant AI therapy and neoadjuvant chemotherapy. If major differences between the AIs cannot be found, more than one AI may be used in the future trial.
"Our long-term aim is to establish AI therapy as a standard neoadjuvant treatment option," said Dr. Ellis. "Another goal of this trial is to help us define a patient population that is likely to benefit from neoadjuvant AI treatment. Through genomic analysis we will determine the molecular basis for differences in aromatase inhibitor response."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.